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ABSTRACT
While cannabis is among the most used recreational drugs during pregnancy, the impact
of maternal cannabis use (mCB) on fetal and child development remains unclear. Here, we
assessed the effects of mCB on psychosocial and physiological measures in young children along
with the potential relevance of the in-utero environment reflected in the placental
transcriptome. Children (~3-6 years) were assessed for hair hormone levels, neurobehavioral
traits on the behavioral assessment system for children (BASC-2) survey, and heart rate variability
(HRV) at rest and during auditory startle. For a subset of children with behavioral assessments,
placental specimens collected at birth were processed for RNA-sequencing. Hair hormone
analysis revealed increased cortisol levels in mCB children. In addition, mCB was associated with
greater anxiety, aggression, and hyperactivity. Children with mCB also showed a reduction in the
high frequency component of HRV at baseline, reflecting reduced vagal tone. In the placenta,
there was reduced expression of many genes involved in immune system function including type
I interferon, neutrophil, and cytokine signaling pathways. Finally, several of these mCB-linked
immune genes organized into co-expression networks that correlated with child anxiety and
hyperactivity. Overall, our findings reveal a relationship between mCB and immune response
gene networks in placenta as a potential mediator of risk for anxiety-related problems in early
childhood.
Keywords: maternal cannabis use, anxiety, cortisol, heart rate variability, placenta, immune
system, cannabinoid receptor 1
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SIGNIFICANCE STATEMENT
Cannabis use is becoming more prevalent, including during developmentally sensitive
periods such as pregnancy. Here we find that maternal cannabis use was associated with
increased cortisol, anxiety, aggression, and hyperactivity in young children. This corresponded
with wide-spread reductions in immune-related gene expression in placenta which correlated
with anxiety and hyperactivity. Future studies are needed to examine the effects of cannabis on
immune function during pregnancy as a potential regulatory mechanism shaping
neurobehavioral development.
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INTRODUCTION
Along with the progressive legalization of recreational cannabis across the world, there is
a prevalent misconception that cannabis use is without significant health risks. In line with this
softening public perception, cannabis has emerged as one of the most consumed recreational
drugs of abuse during pregnancy, with past month cannabis use ranging from 3 to 16 % among
pregnant women (1, 2). In addition, the concentration of the psychoactive component in
cannabis, tetrahydrocannabinol (THC), has increased consistently over the past decade, further
increasing its potential harm (3). Gestational development is highly vulnerable to environmental
factors which are transduced by the mother through the placenta to impact fetal health (4).
Indeed, THC freely passes from the maternal blood to the fetus via the placenta (5). Thus,
although cannabis is considered to provide relief from symptoms such as nausea during
pregnancy (6), it may also present a significant xenobiotic challenge to the developing fetus (7).
THC targets the endocannabinoid system in both the placental tissue and developing
brain (8, 9), highlighting the vulnerability of the developing fetus to prenatal cannabis exposure.
Maternal cannabis use during pregnancy is associated with fetal growth restriction (7, 10), low
birth weight (7, 11) and preterm birth (12). Ex-vivo treatment of placenta with THC (40 µM)
increasing levels of the endocannabinoid anandamide (13). Moreover, rodent studies have
demonstrated that THC exposure during gestation induces growth restriction and alters placental
vasculature (14). Neurobiological consequences are also evident. Cannabis use during pregnancy
is associated with reduced dopaminergic receptor expression in fetal brain (15, 16), altered
cognitive development (17), increased incidence of autism (18) and depression and psychosis
symptomology (19, 20). Preclinical studies directly examining the effects of THC and cannabinoid
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(CB) receptor agonists during pregnancy also report adverse effects on adult offspring such as
anxiogenic phenotypes (21), altered learning behavior (22), and increased drug-seeking behavior
(23). Collectively, this evidence suggests that cannabis use or THC during pregnancy may exert
long-lasting effects on neurobehavioral development.
Despite the abundance of evidence associating maternal cannabis use with fetal health
and child development independently (24), few studies have concurrently investigated the role
of the in-utero environment. This is noteworthy as many clinical and preclinical studies have
elucidated an important role for the placenta in the neurodevelopmental effects associated with
prenatal exposures such as chronic stress (25). Therefore, in the current study, we examined the
effect of maternal cannabis use on the placental transcriptome in relation to offspring
development, leveraging a longitudinal cohort of mother-child dyads from the New York
metropolitan area. The results provide a unique multimodal interrogation of the impact of
maternal cannabis use.

RESULTS
Demographics
The present study utilized longitudinal assessments from a total cohort of 322 motherchild dyads (see Table 1 for demographics and Figure S1 for consort flow chart). Maternal
cannabis use (mCB) was associated with reduced maternal and paternal age and more singlemother pregnancies, state anxiety, trait anxiety, depression, and cigarette smoking. There was
also a significant difference in the race demographic including slightly more African American
(25.4 vs 19.1%), and less Caucasian (12.7 vs 21.5%), and Asian (4.2 vs. 10.4%) mCB cases vs. non5

cannabis users (non-CB). As a result, each of these presented confounds were adjusted for in all
subsequent analyses. Notably, there was no difference across all measures of perinatal health or
frequency of pregnancy complications for mCB vs. non-CB cases.
Steroid hormone analysis
Hair samples (taken close to the scalp from the posterior vertex of the head) collected

from young children were used to evaluate stable steroid hormone concentrations accumulated
over recent months (26) (see upper panel of Table 2). The results revealed increased cortisol
levels in mCB children (F(1,220)=15.67, adj. p<0.0001). There were no significant group differences
for cortisone, DHEA, or cortisol:DHEA ratio.

Neurobehavioral profile: clinical and adaptive behaviors
To assess neurobehavioral traits in early childhood, we utilized the Behavior Assessment
System for Children-2 (BASC-2) (27) as reported in the lower panel of Table 2. The BASC-2 is a
well-standardized, multidimensional evaluation of the behavior of young children which measures
clinical dimensions of behaviors. The instrument produces standardized T-scores, with 50 being the
mean and 10 being the standard deviation, which is normalized for the sex and age for the category.
Here, we found that mCB was associated with increased anxiety (F(1,298)=16.73, adj. p=0.002),
aggression (F(1,298)=10.07, adj. p<0.001), and hyperactivity (F(1,298)=8.50, adj. p<0.001). In addition,
when we evaluated neurobehavioral problems meeting a clinically significant threshold (>60 on
BASC-2), mCB was associated with significantly increased risk for clinical-level problems with
aggression, anxiety, and hyperactivity (Table S1). Next, we evaluated BASC-2 measures for mCB
× child sex interaction effects (Table S2). There was a significant mCB × sex interaction for
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aggression (F(1,296)=4.96, adj. p=0.027) and univariate post-hoc tests revealed a significant
increase in aggression specifically in mCB females (F(1,135)=20.85, adj. p<0.001) and not males
(F(1,163)=1.87, adj. p>0.05).

Heart rate variability
Heart rate variability (HRV) describes the change in time interval between heart beats.
HRV measured in the high frequency (HF) domain is associated with active engagement of the
parasympathetic nervous system (28). Reductions in HF-HRV are linked with various anxietyrelated disorders in both adults and children (29). Here we examined HRV during three sequential
one-min testing phases (pre-startle, intermittent auditory startle, and post-startle). As reported
in Table 3, when we evaluated HF-HRV normalized to low frequency (LF)-HRV (reflecting
parasympathetic/sympathetic balance), there was a significant main effect of mCB (F(1,144)= 5.67,
p=0.02) and significantly reduced HF-HRV both pre-startle (F(1,146)=4.30, p=0.04) and during
startle (F(1,146)=6.37, p=0.01) for mCB children. There were no differences in heart rate or startle
response magnitude/amplitude between mCB vs. non-CB groups (data not shown). For the
subset of subjects with both BASC-2 and HRV measures (N=126 subjects), there was no
relationship between behavioral traits such as anxiety and HF-HRV or normalized HF-HRV (see
Table S3).

Maternal cannabis use and the placenta transcriptome
Placental biopsies were collected at the time of birth (gestational age: 39.13 +/- 2.63
weeks, µ+/-SD) and processed for RNA sequencing to carry out gene expression analysis (see
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Table S4 for demographics and Dataset S1 and Figure S2 for RNA-seq quality metrics).
Differential expression analysis revealed 480 significant genes (359 decreased, 121 increased) in
mCB placentas at p<0.05 (Figure 1A, Figure S3, Dataset S2) with no genes passing false discovery
rate (FDR)-adjustment (q < 0.05). While the high stringency of accounting for numerous
covariates limited our statistcal power to pass FDR-adjustment, we evaluated the function of
significant unadjusted genes (p<0.05) which allows the possibility to identify potential
transcriptome pathways to inform future validation studies. Among the most robustly
differentially expressed genes (DEGs) were many proinflammatory cytokines and chemokines
(e.g., IL1B, CXCL8) which were also reduced in mCB placentas (Figure 1A). Cannabinoid receptor
1 (CNR1) was among the significantly reduced genes and was inversely correlated with weekly
cannabis use (R= -0.64, p<0.05; Figure 1B). Gene ontology analysis revealed that DEGs were
significantly enriched for immune response functions including type I interferon pathway,
cytokine-mediated signaling, and neutrophil migration (Figure 1C, Dataset S3). Using a more
stringent significance criterion (>1.5 fold change), 86 genes remained differentially expressed
with gene ontology enrichment for neutrophil-related functions (Figure 1C). Examining immune
cell-type marker genes previously identified with single cell RNA-seq in term placenta (30)
(Dataset S4), Fisher’s exact tests revealed significant enrichment of mCB DEGs among monocyte
marker genes (OR=6.30, p<0.001; Figure 1D).
To further examine the functional organization of immune genes associated with mCB,
we constructed gene co-expression modules using multiscale embedded gene network analysis
(MEGENA)(31). This identified six hundred interconnected genes modules (i.e., one gene can be
present in multiple modules) ranging from 10-1000 genes per module (Figure 2A, Dataset S5).
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Among these networks, many of the key driver genes (i.e., those with the strongest intra-network
correlations) were significantly reduced in mCB placentas including monocyte-marker genes
(e.g., S100A8) and interferon-induced genes (e.g., OAS1) (Figure 2A, Dataset S6). Furthermore,
Fisher’s exact tests revealed 23 modules enriched for mCB DEGs with most containing top gene
ontology categories involved in immune signaling pathways (Figure 2B, Dataset S6).

Placental immune gene networks are associated with behavioral traits in early childhood
We next examined the relationship between the 23 mCB-associated placental gene
networks and neurobehavioral traits. We found that module eigengene values for three mCBlinked networks were significantly associated with heightened anxiety (Figure 2C, Figure S4,
Dataset S6). Directly examining the mCB-linked DEGs within these networks, major
histocompatibility complex genes (HLA-A/B/F) involved in adaptive immunity, as well as
interferon-induced genes (IFI-35) supporting innate immunity, were among DEGs most
associated with elevated anxiety (Figure 2D, Dataset S7). In addition, we found two mCB-linked
networks with eigengenes significantly correlated with hyperactivity levels (Figure S5A, Dataset
S6). Each network featured the differentially expressed proinflammatory cytokines IL1B and
CXCL8 which were significantly associated with hyperactivity levels (Figure S5B, Dataset S7).

DISCUSSION
The present study identified significant relationships between cannabis use during
pregnancy and many facets of early childhood development. Collectively, we report increased
hair cortisol levels, elevated anxiety, aggression, and hyperactivity and a reduction in normalized
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HRV associated with maternal cannabis use (mCB). In placenta, mCB was associated with reduced
immune-related gene expression including proinflammatory cytokines and immune cell-type
markers. Using gene co-expression analysis, we revealed immune-related gene networks in
placenta significantly correlated with anxiety problems and hyperactivity. Overall, the results
indicate a novel association between the placental transcriptome and developmental trajectories
related to in utero cannabis exposure.
In line with previous investigations reporting greater risk for psychiatric illness in mCB
children with prenatal cannabis exposure (18, 32), the current study showed that mCB is
associated with increased anxiety, aggression, and hyperactivity in young children. Moreover,
along with several altered psychobehavioral traits, mCB children exhibited endocrine and
physiological phenotypes consistent with aberrant stress and anxiety regulation. First, mCB
children had increased hair cortisol, a biomarker for long-term HPA activity. Early life HPA
dysregulation is a risk for mental health disorders over the lifetime (33). Second, mCB decreased
HRV, a measure of cardiac modulation of the autonomic nervous system, suggesting attenuated
parasympathetic tone in mCB children. Low resting HRV variability is associated with multiple
anxiety-related disorders in both young children and adults and is a risk factor for cardiovascular
disease (29). Moreover, low anticipatory HRV is associated with increased stress-induced cortisol
(34). Thus, while we did not observe significant relationships across behavioral assessments for
the subset of children evaluated across multiple assessments in the current study, more robust
inter-subject assessments will be important for future studies. Altogether, the current
multimodal assessment revealed several novel phenotypes associated with stress and emotional
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dysregulation in mCB children that will be important measures for continued longitudinal and
mechanistic evaluation.
The finding that maternal cannabis use is correlated with reduced CNR1 expression in
placenta may reflect an adaptive response of the fetal endocannabinoid system as CNR1 and
brain cannabinoid (CB) receptor expression is normally reduced in human cannabis users (35). In
rodents, prenatal THC reduces CNR1 protein levels in the gestational cortex (36). As CNR1 is
highly expressed in the brain, particularly in limbic regions like hippocampus and amygdala (37)
which contribute to stress regulation and anxiety, fetal endocannabinoid disturbances have
implications for neurodevelopment and emotional regulation. Thus, monitoring endcannabinoid
signaling in the placenta may be a valuable non-invasive indicator of in utero cannabis exposure
severity.
The current finding of significant gene expression alterations centered on the placental
immune-related transcriptome of mCB cases is intriguing. Pregnancy requires well-coordinated
immunological activity, promoting maternal tolerance, while maintaining innate immune activity
to protect against pathogens and viruses (38). For example, this delicate balance is reflected by
type I interferon-mediated signaling in placenta which is essential for preventing viral replication,
yet can also lead to significant pathology and fetal mortality (39). The reduced immune-related
gene expression observed in the placenta of cannabis users mirrors other studies and is
consistent with an immunosuppressive role for cannabinoids. For instance, in preclinical studies,
THC during pregnancy suppresses the cytokine-sensitive STAT3 signaling pathway in the placenta
(40). Moreover, experienced cannabis users have reduced monocyte chemotaxis in response to
CB1 receptor agonists (41) and CB2 agonists modulate monocyte migration via reduced
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interferon-γ activation (42). Both interferon-signaling genes and several monocyte markers were
prominently reduced in mCB placentas in the current study.
Within gene co-expression networks enriched for differentially expressed genes, those
most linked with increased child anxiety were HLA-A/B-F which encode major histocompatibility
complex (MHC)-proteins. MHC-proteins are cell-surface antigen-presenting proteins recognized by
T-cells to promote adaptive immune activation. Induction of HLA gene expression can be triggered
by the interferon-signaling pathway (43) which was among the gene ontologies associated with
mCB use. Reduced basal expression of immune activating genes could potentially increase
vulnerability to pathogens or viruses during pregnancy. For instance, the infection efficacy of Zika
virus is mediated by suppression of the interferon-signaling pathway (44). Importantly, the immune
system (and thereby immune-related gene expression) is intertwined with stress, metabolic, and
microbial environments (45). In addition, the complete impact of mCB on immune function (i.e.
activation, suppression) cannot be evaluated from placenta gene expression alone. It will be critical
for future human studies to examine cytokines over the course of pregnancy and their associations
with other signaling factors in other tissues such as maternal and fetal cord blood in addition to
placentas. Overall, our findings suggest that the immune-modulating effects previously associated
with cannabis and THC may be pertinent to gestational development.
The potential risks of immune system dysregulation during pregnancy to offspring
development have been studied with both activating and suppressing exogenous
immunomodulators. For example, abuse of non-steroidal anti-inflammatory drugs (NSAIDs) has
been linked to miscarriage and altered fetal maturation (46). In addition, maternal immune
activation in rodents increases anxiety and depression phenotypes in offspring (47). Here we
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found that mCB-linked suppression of immune-related gene networks in placenta correlated with
increased anxiety and hyperactivity phenotypes. Previously, socioeconomically-disadvantaged
pregnant mothers were found to have reduced IL-8 levels in serum during third trimester that
associated with increased neurological deficits (48). In rodents, prenatal stress induces placental
inflammation linked to hyperactivity in males (49). While we observed a reduction in
proinflammatory cytokine signaling genes like IL1B and CXCL8 in association with increased
hyperactivity, this finding may reflect the importance of balanced immune regulation during
pregnancy. More mechanistic preclinical studies are needed to directly and concurrently evaluate
the impact of cannabinoids on the placental immunotranscriptome and offspring
neurobehavioral development.
The current report has important limitations. First, in order to reduce stigma, the accuracy
of our self-reported cannabis use was not verified. Furthermore, there was not sufficient power
to examine prenatal and postnatal cannabis use separately and thus the findings can only be
interpreted broadly as maternal cannabis use. However, it is likely that some mothers reporting
postnatal use were also prenatal users and the correlation evident between maternal cannabis
use and placental CNR1 expression shows that the self-report information is robust to detect
expected biological changes. Another limitation relates to the fact that differentially expressed
genes identified in mCB+ placentas did not pass false discovery rate adjustment for multiple
comparisons. Thus, further studies aimed at validating key findings, such as reduced CNR1 gene
expression, will be necessary. Fourth, while we controlled for various confounds, maternal
cannabis use had significant differences in demographic profile and it is difficult to rule out
important interaction effects (e.g., cannabis × stress or cannabis × nicotine) or other potential
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unmeasured confounds influencing child outcomes (e.g., parental investment) contributing to
the main effects. Finally, while many assessments were made in the current study, most motherchild dyads did not undergo all evaluations. This may have limited our ability to detect robust
correlations across different measures such as between HRV and behavioral traits.
In summary, maternal cannabis use is associated with anxiety-related traits during early
childhood in addition to altered stress hormones levels and psychophysiological activity. The
heightened anxiety associated with reduced placental gene expression within immune response
coexpression networks suggests that child development may be linked to in-utero
immunomodulatory effects of cannabis. These results have significant implications for defining
mental health risks attributable to cannabis use during pregnancy.

MATERIALS AND METHODS

Procedures and participants
The study cohort was comprised of mother-child dyads from an on-going Stress In
Pregnancy project (50). Expectant mothers were recruited from obstetrics clinics at Mount Sinai
Hospital and New York-Presbyterian/Queens in New York City. Women were excluded based on
HIV infection, maternal psychosis, maternal age < 15 years, life-threatening maternal medical
complications, and congenital or chromosomal abnormalities in the fetus. Written informed
consent was obtained from eligible women for all procedures. The Institutional Review Boards at
the City University of New York, Icahn School of Medicine at Mount Sinai, and New York
Presbyterian/Queens approved the study. Demographic and clinical information were obtained
at an initial face-to-face evaluation with a social worker as previously described (50). Annual
14

assessments continued at CUNY Queens College. At each annual visit, children’s neurobehavioral
development and mother’s psychological functioning were ascertained. [As child behavioral,
hormonal, and psychophysiological assays were each carried out during separate evaluations with uneven
participation, group sizes varied across analyses (see Tables 2 and 3).

Hair hormone levels
Cortisol, cortisone, and dehydroepiandrosterone (DHEA) were measured in hair samples
collected in children at ~36 months. Briefly, a bundle of ~100 hairs was cut from the posterior
vertex of the child’s head, close to the scalp. Samples of 3 cm section were processed using
methanol extraction and assayed (Kirschbaum’s laboratory, Dresden, Germany)(51).

Behavioral and emotional functioning during childhood
Clinical dimensions of child behavior and emotions were ascertained by administering the
Behavior Assessment System for Children-2 (BASC-2) to parents (27). Dimensions included
Hyperactivity, Aggression, Anxiety, Depression, Somatization, Atypicality, Withdrawal, and
Attention Problems. The standardized t-score assessment was generated based on the child’s
biological age and sex. The mean age (SD) at the time of the assessments was 44.9 (10.9) months.
Furthermore, we tested the effect of maternal cannabis use on clinically significant and at-risk
conditions; in accordance with the BASC-2 manual, scores >60 on the standardized dimensions
reflect clinical diagnosis with a behavioral or emotional problem.

Electrocardiogram analysis of heart rate variability
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Electrocardiogram (ECG) recordings were made using the BIOPAC MP150 system (Biopac
Inc., CA) and ECG100C BioNomadix amplifier with three pre-jelled Ag-AgCl disposable vinyl
electrodes placed at the upper left collarbone, upper right collarbone, and lower left ribcage with
a bandpass filter of 60 Hz. ECG signals were visually inspected for artifacts and corrected for false
or undetected R-waves in AcqKnowledge 4.4. Heart rate variability (HRV) was quantified by
spectral analysis of the inter-beat (RR) interval series analyzed at both high-frequency (HF) (0.150.40 Hz) and low frequency (LF) (0.04-0.24 Hz) power. Log10 transformation was applied to correct
the skewed distribution of HF and LF measures. The normalized HRV was computed by calculating
log10(HF-HRV/LF-HRV).
The psychophysiological assessment was carried out in children between 48-72 months
with mean (SD) age of 54.39 (1.95) months. The testing session began with a 1-min rest period
during which children were instructed to sit still and be quiet, followed by a 1-min startle
paradigm, presented on the computer monitor. The startle paradigm involved a calm video
suddenly interrupted by six startle probes of tone burst at 90 dB. After the startle paradigm, there
was another 1-min resting period with continued ECG monitoring. Throughout testing, the
mother sat next to the child and could talk to the child to maintain the child’s attention and
stillness. Notably, during the trial, measurements of electrodermal activity (EDA) were also
recorded. However, since useable data was recovered for only a small percentage (<25%) of the
experimental cohort, we were not able to perform statistical analysis for startle magnitude and
amplitude.

Statistical Analysis
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Self-report of either prenatal or postnatal cannabis use were collectively considered
“maternal cannabis use” throughout the present study. Parental age, education, marital status,
prenatal substance use, child’s sex, child’s age, and race were a priori defined as confounders.
Additionally, aspects of maternal stress including pregnancy during Hurricane Sandy in 2012 and
measures of maternal state/trait anxiety (derived from the State Trait Anxiety Inventory) were
controlled for in all statistical models.
For the statistical analysis, descriptive statistics were first conducted to evaluate mean
and standard deviation (SD) of outcome variables. General Linear Model (GLM) was used as the
primary analytical method. Univariate GLM was used for hair hormones. For neurobehavioral
(BASC-2) outcomes, a multivariable GLM was used which adjusts for correlations among
dependent variables. The effect of mCB on values of neurobehavioral outcomes (i.e., classifying
children with at-risk and clinically significant problems) was tested with the ordinal logistic link
function in GLM. The exponentiation of the β-coefficient was obtained to calculate the odds ratio
(OR) and associated 95% confidence interval (CI). Prior to the analysis, each subscale was
evaluated for normality. If the assumption of univariate normal distribution was violated, logtransformation was applied to achieve normality. Finally, the electrocardiogram assessments of
HRV used a linear mixed-effects model with trial as repeated measure and subject as a random
effect along with univariate GLM tests for each trial as presented in the results table. Age at the
time of testing was also included as a covariate for this assessment.

Placental Tissue Collection
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Placental samples were acquired and processed as previously described (50). Briefly,
biopsies from the outer layer of the blastocyst, free of maternal decidua, were collected from each
placenta quadrant midway between the cord insertion and the placenta rim within an hour of
delivery. Specimens were frozen in liquid nitrogen and stored at -80°C.

RNA sequencing data analysis
Transcriptome analysis (RNA-sequencing; RNA-seq) was carried out on a representative
subset (N=131) of the total cohort. RNA was extracted from pulverized placental tissue and
processed to remove ribosomal RNA and prepare sequencing libraries (Ribo-Zero Kit and TruSeq
commercial kits; Illumina Inc., San Diego, CA). Libraries were then paired-end sequenced (2 x 75
bp) at a depth of 28.0 +/- 0.3 million reads (conducted by Novogene Corp, Sacramento, CA). Fastq
sequencing output was then mapped to the hg38 genomic assembly using the STAR read aligner
with standard mapping parameters. Uniquely mapped reads (91.6 +/- 1.73 % (µ+/-SD) of total
reads) were annotated to genomic features from the Ensembl genome database and quantified
using the –quantMode argument in STAR. Uniquely mapped reads with minimal average
expression (<0.3 Fragments per Kilobase Million) were removed prior to subsequent analyses. All
samples were evaluated with principal component analysis (PCA) to confirm absence of technical
outliers (Figure S2).
For differential gene expression analysis, all group comparisons were made using the R
package DESeq2 for moderated estimation of fold-change and statistical analysis. All analyses
were performed examining main effects of mCB on each gene with a general linearized model
weighted for library sizes and gene-level variance. The model accounted for many covariates with
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maternal age, paternal age, fetal weight, and maternal trait anxiety evaluated as continuous
variables and pregnancy during Hurricane Sandy, cigarette smoking, alcohol use, fetal sex, marital
status, race, and educational attainment as discrete variables. While FDR-adjustment was
applied, significant genes with uncorrected p-values were also considered in order to elucidate
gene-sets and networks that can be directly tested evaluated in future studies without falsediscovery burden. Identified differentially expressed genes (DEGs) were used for gene set
enrichment analyses using the curated transcriptional, pathway, and ontology libraries managed
on the Enrichr web server. All gene ontology analysis utilized the databases from the Gene
Ontology Consortium and statistical significance was determined with Fisher’s Exact Test in the
Enrichr R package (52). Placental immune subtype-specific genes were defined using marker
genes previously identified with single-cell RNA-seq in human term placenta (30).
Multiscale embedded gene co-expression analysis (MEGENA) was performed on all
protein coding genes using the R package MEGENA. Briefly, Pearson correlation coefficients
(PCCs) were computed for all gene pairs to identify all significant gene pair correlations (FDR-adj.
p < 0.05). Next, planar filtered network (PFN) and multiscale clustering analyses were carried out
to identify co-expression modules with 10/1000 set as min/max module sizes. Significance testing
for overlap between DEGs and network module gene sets was performed using one-tailed
Fisher’s exact test with Benjamini & Hochberg false discovery rate adjustment (q < 0.05). Module
eigengenes values were calculated with the moduleEigengenes function in the WGCNA R package
(53). In calculating eigengenes, all gene members of each module were considered. Point-biserial
or spearman correlations was used to associate eigengenes/genes with dichotomous and
continuous neurobehavioral traits, respectively.
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Data availability
The RNA-sequencing datasets generated and analyzed in the current study were
submitted to the NCBI Sequence Read Archive (accession: PRJNA719417) and Gene Expression
Omnibus (accession: GSE179930). All software used for transcriptomic analyses are publicly
available.
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TABLE AND FIGURE LEGEND
Table 1: Demographics and reproductive characteristics of study participants.

Table 2: Maternal cannabis use in relation to steroid hormones levels and behavioral traits in
early childhood.

Table 3: Maternal cannabis use (mCB) in relation to heart rate variability (HRV) in early
childhood.

Figure 1: Maternal cannabis use (mCB) is associated with reduced immune-related gene
expression in placenta. (A) Volcano plot showing differentially expressed genes (DEGs) for mCB
placentas (DEGs < 1.5 fold change (FC) = red points, DEGs > 1.5 FC = blue points). Note: 1.5 FC ~
0.58 log2 FC on x-axis. (B) Significant inverse correlation between self-reported prenatal cannabis
use and placental CNR1 gene expression (R = 0.64, p < 0.05). (C) Gene ontology analysis revealed
that all DEGs (top) and DEGs > 1.5 fold change (bottom) were enriched for immune-related gene
sets. (D) Log fold changes (mCB vs. non-CB) for immune cell-type marker genes in placenta (mCB
DEGs in red (<1.5 FC) or blue (>1.5 FC) with bars depicting median). NK-cell = Natural killer cell.

Figure 2: Maternal cannabis use is associated with placental gene co-expression networks
related to immune function and heightened anxiety. (A) Multiscale embedded gene coexpression network comprised of highly correlated gene modules. Arrows zoom in on two
modules significantly enriched for mCB DEGs. Red nodes = DEGs. Diamond shape = network hub
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genes. Darker edges between nodes represent stronger gene-gene correlations. (B) Bubble plot
showing modules (blue circles) that are most significantly enriched for mCB DEGs are also
enriched for immune-related gene ontology terms. (C) Heatmap of correlation coefficients
between module eigengenes and child behavioral problems. Rows feature all modules enriched
for mCB DEGs annotated with a unique color and top gene ontology term. *= p<0.05. (D) For each
mCB DEGs in the teal, pink, and red (see panel C) modules correlated with anxiety, correlation
coefficients with anxiety (x-axis) and the -log10 transformed p-values (y-axis) are depicted. Dash
line represents significance threshold for gene-anxiety correlations.
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